Economic evaluation of carfilzomib (car), ixazomib (ixa), elotuzumab (elo), or daratumumab (dar) with lenalidomide & dexamethasone (len+dex) vs len+dex in relapsed/refractory multiple myeloma (r/r mm)

• In: Poster presentation
• At: Seoul (South Korea) (2017)
• Type: Poster
• Poster code: POS-SAPS-002
• By: ABRAHAM, Ivo (University Of Arizona, Pharmacy Practice and Science, Tucson, United States)
• Co-author(s): Nimer Alsaid: Center for Health Outcomes and PharmacoEconomic Research, University Of Arizona College of Pharmacy, Tucson, United States
  Ali McBride: Banner University Medical Center , Tucson, United States;, University of Arizona Cancer Center, Tucson, United States
  Abdulaali Mutairi: Center for Health Outcomes and PharmacoEconomic Research, University Of Arizona College of Pharmacy, Tucson, United States
  Amit Agarwal: Banner University Medical Center, Tucson, United States;, University of Arizona Cancer Center, Tucson, United States
  Faiz Anwer: Banner University Medical Center, Tucson, United States;, University of Arizona Cancer Center, Tucson, United States
  Ivo Abraham: Center for Health Outcomes and PharmacoEconomic Research, University Of Arizona College of Pharmacy, Tucson, United States
  
• Abstract:

  Background

  CAR, IXA, ELO, and DAR in triplet combination with LEN+DEX have shown superior efficacy over LEN+DEX in R/R MM, but their comparative efficacy and cost effectiveness have not been estimated.

  Purpose

  To perform cost-effectiveness and cost-utility evaluations for the four triplet regimens used in R/R MM.

  Methods

  Network meta-analysis [NMA] and ..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login